Abstract
Recombinant Interleukin 4 was administered by subcutaneous injection at daily doses of 0.5, 1.0 or 5.0 micrograms kg-1 to nine patients as part of a Phase I Dose Toxicity Study. Dose limiting toxicity was reached at 5 micrograms kg-1 day-1. Symptoms of toxicity included fatigue, 'flu like symptoms and elevated liver enzymes. Modest but significant elevations of neutrophil and platelet counts occurred. No clear evidence of antitumour effects emerged although pain in metastatic lymph nodes and a small fall in myeloma paraprotein levels during dosing were observed. In vitro and murine in vivo studies indicate that patients with lymphoproliferative disease should be selected for Phase II trials.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gilleece, M., Scarffe, J., Ghosh, A. et al. Recombinant human interleukin 4 (IL-4) given as daily subcutaneous injections – a phase I dose toxicity trial. Br J Cancer 66, 204–210 (1992). https://doi.org/10.1038/bjc.1992.243
Issue Date:
DOI: https://doi.org/10.1038/bjc.1992.243
This article is cited by
-
IL-4 as a Repurposed Biological Drug for Myocardial Infarction through Augmentation of Reparative Cardiac Macrophages: Proof-of-Concept Data in Mice
Scientific Reports (2017)
-
Protective effects of IL-4 on Bacillus Calmette-Guerin and lipopolysaccharide induced immunological liver injury in mice
Inflammation Research (2012)
-
STAT6 Mediates Interleukin-4 Growth Inhibition in Human Breast Cancer Cells
Neoplasia (2002)
-
Interleukin-10 produced by recombinant adenovirus prolongs survival of cardiac allografts in rats
Gene Therapy (2000)